{"id":64722,"date":"2026-05-08T14:47:26","date_gmt":"2026-05-08T06:47:26","guid":{"rendered":"https:\/\/flcube.com\/?p=64722"},"modified":"2026-05-08T14:47:26","modified_gmt":"2026-05-08T06:47:26","slug":"gilead-sciences-reports-4-revenue-growth-in-q1-2026-driven-by-hiv-portfolio-strength-and-trodelvy-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64722","title":{"rendered":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion"},"content":{"rendered":"\n<p><strong>Gilead Sciences, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) reported <strong>first quarter 2026 revenues of $7.0 billion<\/strong>, representing a <strong>4% year-over-year (YOY) increase<\/strong>, with core product sales (excluding Veklury) growing <strong>8% to $6.8 billion<\/strong>. The company&#8217;s performance was primarily driven by <strong>robust HIV product demand<\/strong>, <strong>rapid Trodelvy growth<\/strong>, and the successful launch of <strong>Livdelzi<\/strong>, partially offset by expected declines in <strong>Veklury<\/strong> and <strong>chronic hepatitis C virus (HCV)<\/strong> products.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>$7.0 billion<\/td><td>+4%<\/td><td>HIV portfolio, Trodelvy, Livdelzi<\/td><\/tr><tr><td><strong>Core Product Sales<\/strong> (ex-Veklury)<\/td><td>$6.8 billion<\/td><td>+8%<\/td><td>Underlying business momentum<\/td><\/tr><tr><td><strong>Net Income<\/strong><\/td><td>$1.8 billion<\/td><td>-2%<\/td><td>Higher R&amp;D investment, product mix<\/td><\/tr><tr><td><strong>EPS (Diluted)<\/strong><\/td><td>$1.45<\/td><td>-3%<\/td><td>Share count impact, investment priorities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-portfolio-performance-analysis\">Portfolio Performance Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hiv-franchise-continued-market-leadership\">HIV Franchise \u2013 Continued Market Leadership<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total HIV Sales<\/strong>: $5.0 billion (+10% YOY)<\/li>\n\n\n\n<li><strong>Biktarvy<\/strong>: $3.4 billion (+7% YOY) \u2013 maintaining dominant market position<\/li>\n\n\n\n<li><strong>Descovy<\/strong>: $807 million (+38% YOY) \u2013 strong growth driven by PrEP and treatment indications<\/li>\n\n\n\n<li><strong>Market Dynamics<\/strong>: Sustained demand despite generic competition in older regimens; premium positioning of Biktarvy intact<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-portfolio-accelerating-growth-trajectory\">Oncology Portfolio \u2013 Accelerating Growth Trajectory<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trodelvy (sacituzumab govitecan-hziy)<\/strong>: $402 million (+37% YOY)<\/li>\n\n\n\n<li><strong>Growth Drivers<\/strong>: Higher demand across multiple indications, favorable inventory dynamics, increased average realized price<\/li>\n\n\n\n<li><strong>TROP2 ADC Leadership<\/strong>: Establishing strong foothold in competitive antibody-drug conjugate market<\/li>\n\n\n\n<li><strong>Cell Therapy<\/strong>: $407 million (-12% YOY)<\/li>\n\n\n\n<li><strong>Yescarta<\/strong>: $332 million (-14% YOY) \u2013 temporary headwinds from manufacturing capacity constraints<\/li>\n\n\n\n<li><strong>Tecartus<\/strong>: $75 million (-4% YOY) \u2013 stable performance in mantle cell lymphoma indication<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-liver-disease-portfolio-mixed-results\">Liver Disease Portfolio \u2013 Mixed Results<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Liver Disease Sales<\/strong>: $767 million (+1% YOY)<\/li>\n\n\n\n<li><strong>Livdelzi (seladelpar)<\/strong>: Strong launch momentum contributing to portfolio growth<\/li>\n\n\n\n<li><strong>HCV Products<\/strong>: Continued decline due to curative nature of therapy and reduced screening rates<\/li>\n\n\n\n<li><strong>Inventory Impact<\/strong>: Unfavorable inventory dynamics partially offsetting Livdelzi success<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-covid-19-therapeutics-expected-decline\">COVID-19 Therapeutics \u2013 Expected Decline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Veklury (remdesivir)<\/strong>: $144 million (-52% YOY)<\/li>\n\n\n\n<li><strong>Primary Driver<\/strong>: Significantly lower rates of COVID-19-related hospitalizations<\/li>\n\n\n\n<li><strong>Strategic Context<\/strong>: Managed decline as pandemic transitions to endemic phase<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-business-highlights\">Strategic Business Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-execution-excellence\">Commercial Execution Excellence<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV Portfolio Resilience<\/strong>: Demonstrated ability to maintain premium pricing and market share leadership<\/li>\n\n\n\n<li><strong>Trodelvy Momentum<\/strong>: Rapid adoption across breast cancer and urothelial cancer indications<\/li>\n\n\n\n<li><strong>Livdelzi Launch Success<\/strong>: Positive initial reception in primary biliary cholangitis (PBC) market<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pipeline-investment-priorities\">Pipeline Investment Priorities<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R&amp;D Focus<\/strong>: Increased investment in next-generation HIV therapies, additional TROP2 ADC indications, and liver disease innovations<\/li>\n\n\n\n<li><strong>Manufacturing Capacity<\/strong>: Addressing Cell Therapy supply constraints through facility expansions<\/li>\n\n\n\n<li><strong>Geographic Expansion<\/strong>: International markets contributing to diversified revenue streams<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook-amp-guidance\">Market Outlook &amp; Guidance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-indicators\">Forward-Looking Indicators<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Year Revenue Guidance<\/strong>: Maintained at $28.0\u201329.0 billion range<\/li>\n\n\n\n<li><strong>HIV Portfolio<\/strong>: Expected to deliver low-to-mid single-digit growth for full year<\/li>\n\n\n\n<li><strong>Trodelvy<\/strong>: On track to exceed $1.8 billion in annual sales<\/li>\n\n\n\n<li><strong>Cell Therapy<\/strong>: Recovery expected in second half 2026 as manufacturing capacity increases<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HIV Market<\/strong>: Defending leadership against emerging long-acting injectable competitors<\/li>\n\n\n\n<li><strong>Oncology Space<\/strong>: Competing effectively in crowded TROP2 ADC landscape with differentiated clinical profile<\/li>\n\n\n\n<li><strong>Liver Disease<\/strong>: Establishing Livdelzi as standard of care in PBC while exploring additional indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stock Performance<\/strong>: GILD closed at $82.45 on May 7, 2026; dividend yield of 3.8% provides income support<\/li>\n\n\n\n<li><strong>Valuation Metrics<\/strong>: Trading at 12.5x forward earnings, below historical average reflecting near-term Cell Therapy challenges<\/li>\n\n\n\n<li><strong>Cash Generation<\/strong>: Strong free cash flow supporting dividend payments, share repurchases, and strategic acquisitions<\/li>\n\n\n\n<li><strong>Pipeline Catalysts<\/strong>: Multiple late-stage assets expected to drive long-term growth beyond 2026<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Gilead&#8217;s financial performance, product sales, and strategic initiatives. Actual results may differ due to competitive pressures, regulatory developments, manufacturing challenges, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/GILD-Q126-Earnings-Presentation-7-May-2026.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of GILD-Q126-Earnings-Presentation-7-May-2026.\"><\/object><a id=\"wp-block-file--media-a1060095-6f81-49bf-a329-f4cb24f6c7a6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/GILD-Q126-Earnings-Presentation-7-May-2026.pdf\">GILD-Q126-Earnings-Presentation-7-May-2026<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/GILD-Q126-Earnings-Presentation-7-May-2026.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a1060095-6f81-49bf-a329-f4cb24f6c7a6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64724,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,226,1025],"class_list":["post-64722","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company&#039;s performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64722\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company&#039;s performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64722\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T06:47:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion\",\"datePublished\":\"2026-05-08T06:47:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722\"},\"wordCount\":555,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0802.webp\",\"keywords\":[\"Finanical Reports\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64722#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64722\",\"name\":\"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0802.webp\",\"datePublished\":\"2026-05-08T06:47:26+00:00\",\"description\":\"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company's performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64722\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0802.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0802.webp\",\"width\":1080,\"height\":608,\"caption\":\"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64722#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company's performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64722","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion","og_description":"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company's performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.","og_url":"https:\/\/flcube.com\/?p=64722","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T06:47:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64722#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64722"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion","datePublished":"2026-05-08T06:47:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64722"},"wordCount":555,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64722#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","keywords":["Finanical Reports","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64722#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64722","url":"https:\/\/flcube.com\/?p=64722","name":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64722#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64722#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","datePublished":"2026-05-08T06:47:26+00:00","description":"Gilead Sciences, Inc. (NASDAQ: GILD) reported first quarter 2026 revenues of $7.0 billion, representing a 4% year-over-year (YOY) increase, with core product sales (excluding Veklury) growing 8% to $6.8 billion. The company's performance was primarily driven by robust HIV product demand, rapid Trodelvy growth, and the successful launch of Livdelzi, partially offset by expected declines in Veklury and chronic hepatitis C virus (HCV) products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64722#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64722"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64722#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","width":1080,"height":608,"caption":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64722#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences Reports 4% Revenue Growth in Q1 2026 Driven by HIV Portfolio Strength and Trodelvy Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0802.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64722"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64722\/revisions"}],"predecessor-version":[{"id":64725,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64722\/revisions\/64725"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64724"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}